Synlogic Presents Data from Immuno-Oncology Development Program Demonstrating Potent Anti-Tumor Immunity … – Markets Insider
|
Synlogic Presents Data from Immuno-Oncology Development Program Demonstrating Potent Anti-Tumor Immunity …
Markets Insider Synlogic (Nasdaq: SYBX), a clinical-stage company applying synthetic biology to probiotics to develop novel living medicines, announced the presentation of positive preclinical data from its Synthetic Biotic immuno-oncology (IO) program at the Keystone … |
